Ablaze Pharmaceuticals, a clinical-stage pharmaceutical company with offices in Shanghai and San Diego, has garnered $75 million in its Series A round funding, the firm announced on Monday.
The fresh round was jointly led by AdvanTech Capital and Vivo Capital, a Palo Alto-based investment firm that backs the US and China healthcare market.
